SELLAS Life Sciences Group, Inc. Common Stock
Here’s whether SELLAS Life Sciences Group, Inc. Common Stock (SLS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+17.27% over 10 days); RSI 35 — healthy momentum range; strong 1-year return of +518.6%; 3-month momentum positive (+153.8%). Concerns: declining volume on rally — weak conviction (0.69x 30d avg). Currently 28.7% off its 52-week high. Score: +6/7.
SLS is in a confirmed uptrend, trading above both its 50-day ($10.16) and 200-day ($5.19) moving averages. An RSI of 35.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +518.6% compares to +16.5% for SPY (beat the market by 502.1%). The current 28.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.